Steven Fishbane1, Carol A Pollock2, Mohamed El-Shahawy3, Elizabeth T Escudero4, Anjay Rastogi5, Bui Pham Van6, Lars Frison7, Mark Houser8, Maksym Pola9, Dustin J Little8, Nicolas Guzman8, Pablo E Pergola10. 1. Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York sfishbane@northwell.edu. 2. Department of Medicine, Northern Clinical School, Kolling Institute of Medical Research, The University of Sydney, Sydney, New South Wales, Australia. 3. Department of Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California. 4. Division of Nephrology, Hospital Arzobispo Loayza, Lima, Peru. 5. Department of Medicine, University of California Los Angeles, Los Angeles, California. 6. Department of Nephrology, Urology and Transplantation, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam. 7. Biostatistics, AstraZeneca, Mölndal, Sweden. 8. Global Medicines Development, AstraZeneca, Gaithersburg, Maryland. 9. Global Medicines Development, AstraZeneca, Warsaw, Poland. 10. Renal Associates PA, San Antonio, Texas.
Abstract
BACKGROUND: Concerns regarding cardiovascular safety with current treatments for anemia in patients with dialysis-dependent (DD)-CKD have encouraged the development of alternatives. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing endogenous erythropoietin and iron availability. METHODS: In this open-label phase 3 study, patients with DD-CKD and anemia were randomized 1:1 to oral roxadustat three times weekly or parenteral epoetin alfa per local clinic practice. Initial roxadustat dose depended on erythropoiesis-stimulating agent dose at screening for patients already on them and was weight-based for those not on them. The primary efficacy end point was mean hemoglobin change from baseline averaged over weeks 28‒52 for roxadustat versus epoetin alfa, regardless of rescue therapy use, tested for noninferiority (margin, -0.75 g/dl). Adverse events (AEs) were assessed. RESULTS: Among 2133 patients randomized (n=1068 roxadustat, n=1065 epoetin alfa), mean age was 54.0 years, and 89.1% and 10.8% were on hemodialysis and peritoneal dialysis, respectively. Mean (95% confidence interval) hemoglobin change from baseline was 0.77 (0.69 to 0.85) g/dl with roxadustat and 0.68 (0.60 to 0.76) g/dl with epoetin alfa, demonstrating noninferiority (least squares mean difference [95% CI], 0.09 [0.01 to 0.18]; P<0.001). The proportion of patients experiencing ≥1 AE and ≥1 serious AE was 85.0% and 57.6% with roxadustat and 84.5% and 57.5% with epoetin alfa, respectively. CONCLUSIONS: Roxadustat effectively increased hemoglobin in patients with DD-CKD, with an AE profile comparable to epoetin alfa. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. CLINICALTRIALS: gov Identifier: NCT02174731.
BACKGROUND: Concerns regarding cardiovascular safety with current treatments for anemia in patients with dialysis-dependent (DD)-CKD have encouraged the development of alternatives. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing endogenous erythropoietin and iron availability. METHODS: In this open-label phase 3 study, patients with DD-CKD and anemia were randomized 1:1 to oral roxadustat three times weekly or parenteral epoetin alfa per local clinic practice. Initial roxadustat dose depended on erythropoiesis-stimulating agent dose at screening for patients already on them and was weight-based for those not on them. The primary efficacy end point was mean hemoglobin change from baseline averaged over weeks 28‒52 for roxadustat versus epoetin alfa, regardless of rescue therapy use, tested for noninferiority (margin, -0.75 g/dl). Adverse events (AEs) were assessed. RESULTS: Among 2133 patients randomized (n=1068 roxadustat, n=1065 epoetin alfa), mean age was 54.0 years, and 89.1% and 10.8% were on hemodialysis and peritoneal dialysis, respectively. Mean (95% confidence interval) hemoglobin change from baseline was 0.77 (0.69 to 0.85) g/dl with roxadustat and 0.68 (0.60 to 0.76) g/dl with epoetin alfa, demonstrating noninferiority (least squares mean difference [95% CI], 0.09 [0.01 to 0.18]; P<0.001). The proportion of patients experiencing ≥1 AE and ≥1 serious AE was 85.0% and 57.6% with roxadustat and 84.5% and 57.5% with epoetin alfa, respectively. CONCLUSIONS: Roxadustat effectively increased hemoglobin in patients with DD-CKD, with an AE profile comparable to epoetin alfa. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis. CLINICALTRIALS: gov Identifier: NCT02174731.
Authors: Morgan E Grams; Wei Yang; Casey M Rebholz; Xue Wang; Anna C Porter; Lesley A Inker; Edward Horwitz; James H Sondheimer; L Lee Hamm; Jiang He; Matthew R Weir; Bernard G Jaar; Tariq Shafi; Lawrence J Appel; Chi-Yuan Hsu Journal: Am J Kidney Dis Date: 2017-03-30 Impact factor: 8.860
Authors: Daniel G Wright; Elizabeth C Wright; Andrew S Narva; Constance T Noguchi; Paul W Eggers Journal: Clin J Am Soc Nephrol Date: 2015-09-10 Impact factor: 8.237
Authors: A Besarab; W K Bolton; J K Browne; J C Egrie; A R Nissenson; D M Okamoto; S J Schwab; D A Goodkin Journal: N Engl J Med Date: 1998-08-27 Impact factor: 91.245
Authors: Francesco Locatelli; Peter Bárány; Adrian Covic; Angel De Francisco; Lucia Del Vecchio; David Goldsmith; Walter Hörl; Gerard London; Raymond Vanholder; Wim Van Biesen Journal: Nephrol Dial Transplant Date: 2013-04-12 Impact factor: 5.992
Authors: Erica Chapin; Min Zhan; Van Doren Hsu; Stephen L Seliger; Loreen D Walker; Jeffrey C Fink Journal: Clin J Am Soc Nephrol Date: 2009-12-03 Impact factor: 8.237
Authors: Ughetta Del Balzo; Pierre E Signore; Gail Walkinshaw; Todd W Seeley; Mitchell C Brenner; Qingjian Wang; Guangjie Guo; Michael P Arend; Lee A Flippin; F Aisha Chow; David C Gervasi; Christian H Kjaergaard; Ingrid Langsetmo; Volkmar Guenzler; David Y Liu; Steve J Klaus; Al Lin; Thomas B Neff Journal: J Pharmacol Exp Ther Date: 2020-06-02 Impact factor: 4.030
Authors: Aniket Ramshekar; Colin A Bretz; Eric Kunz; Thaonhi Cung; Burt T Richards; Gregory J Stoddard; Gregory S Hageman; Brahim Chaqour; M Elizabeth Hartnett Journal: Biomedicines Date: 2022-07-09